Active, not recruitingPhase 1NCT00878163

GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery

Studying Acinar cell carcinoma of pancreas

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Charles Erlichman, M.D
Mayo Clinic
Intervention
Diagnostic Laboratory Biomarker Analysis(other)
Enrollment
55 enrolled
Eligibility
18 years · All sexes
Timeline
20092027

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00878163 on ClinicalTrials.gov

Other trials for Acinar cell carcinoma of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Acinar cell carcinoma of pancreas

← Back to all trials